3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positio...
AltaPointe Health, a leading provider of behavioral health services in Alabama, is making strides in addressing substance use disorders among wo...
TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first oral resolution film (ODF) of apixaban. Th...
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) ...
Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...
Theratechnologies Inc., a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine ...
Akeso, Inc. is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Admi...
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, reported its consolidated financial results for the fourth quarter and full year ...
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensi...
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for AD...
SpringWorks Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that the U.S. Food ...
A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now approved for use ...
Novartis announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceut...
GC Biopharma, a South Korean biopharmaceutical company, announced that it presented development updates on its LSD (lysosomal storage disorder) pipelines a...
© 2025 Biopharma Boardroom. All Rights Reserved.
